v3.26.1
Organization and description of business - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended
Dec. 31, 2024
Apr. 30, 2026
Oct. 31, 2025
Mar. 31, 2026
Dec. 31, 2025
Organization And Description Of Business [Line Items]          
Gain (Loss) on Extinguishment of Debt       $ 151,000,000  
Cash and cash equivalents       5,500,000 $ 6,375,000
Accumulated deficit       (308,920,000) $ (307,314,000)
Upfront Payment     $ 3,500,000 3,500,000  
Commercial Milestones And Contingent Value Rights       105,000,000  
Gain (Loss) on Disposition of Other Assets       $ 3,500,000  
Aggregate Purchase Price   $ 350,000,000      
Sale of common stock warrants, net of issuance costs, shares | shares 21,070,220        
Common stock plus pre-funded warrants exercisable 23,041,040        
Offering price $ 0.065        
Net proceeds $ 2,900,000        
Convertible Preferred Stock Par Value   $ 0.001      
Debt issuance cost 27,000        
Proceeds from Issuance of Debt $ 600,000        
Potential Future Net   a pro rata portion of 80% of any potential future net proceeds received by Parent or its affiliates from the development, commercialization, licensing, sale or other disposition of Galera’s product candidate, tilarginine, or related intellectual property during the five years following the closing of the Obsidian Merger and (ii) one CVR for each share of Galera common stock held by such holder, representing the right to receive a pro rata portion of 95% of any potential future net proceeds received by Parent or its affiliates from the Asset Purchase and Sale Agreement with Biossil during the ten years following the closing of the Obsidian Merger.      
Initial Public Offering And Concurrent Private Placements [Member]          
Organization And Description Of Business [Line Items]          
Exercise price | $ / shares $ 0.001